Patents by Inventor Suke Wang

Suke Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7872101
    Abstract: The invention relates to the use of the interaction between the GPR78 polypeptide or the GPR26 polypeptide and their identified ligands and antagonists as the basis for screening methods for the identification of agents that modulate the activity of these receptors, and for diagnostic and therapeutic purposes. The agents identified by the screening methods of the invention have use in the treatment of GPR78- and/or GPR26-mediated disorders, including, but not limited to, neurological disorders (such as anxiety disorders), metabolic disorders, cardiovascular disorders, hormone-related disorders, vascular disorders and hyperproliferative disorders (such as cancer).
    Type: Grant
    Filed: December 3, 2007
    Date of Patent: January 18, 2011
    Assignee: Schering Corporation
    Inventors: Suke Wang, Frederick James Monsma, Jr., Xiaoxin Yang, Eric L. Gustafson, Maureen Laverty, Elizabeth B. Smith
  • Publication number: 20090176254
    Abstract: The present invention provides isolated mammalian GalR3 receptors, isolated or recombinant nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the receptors using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the receptors and are useful for treating medical conditions caused or mediated by galanin. Also provided are screening methods for identifying specific agonists and antagonists of the mammalian GalR3 receptors.
    Type: Application
    Filed: March 11, 2008
    Publication date: July 9, 2009
    Inventors: Marvin Bayne, Tanaz Hashemi, Chaogang He, Suke Wang
  • Patent number: 7547523
    Abstract: The present invention provides an isolated mammalian histamine receptor, isolated or recombinant nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods of making the receptor using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the receptor and are useful for treating medical conditions caused or mediated by histamine. Also provided are screening methods for identifying specific agonists and antagonists of the mammalian histamine receptor.
    Type: Grant
    Filed: January 5, 2007
    Date of Patent: June 16, 2009
    Assignee: Schering Corporation
    Inventors: Jiang X. Behan, Joseph A. Hedrick, Thomas M. Laz, Frederick James Monsma, Jr., Kelley L. Morse, Shelby P. Umland, Suke Wang
  • Publication number: 20090075297
    Abstract: The present invention provides isolated mammalian GalR3 receptors, isolated or recombinant nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the receptors using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the receptors and are useful for treating medical conditions caused or mediated by galanin. Also provided are screening methods for identifying specific agonists and antagonists of the mammalian GalR3 receptors.
    Type: Application
    Filed: August 26, 2008
    Publication date: March 19, 2009
    Inventors: MARVIN BAYNE, Tanaz Hashemi, Chaogang He, Suke Wang
  • Patent number: 7417122
    Abstract: The present invention provides isolated mammalian GalR3 receptors, isolated or recombinant nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the receptors using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the receptors and are useful for treating medical conditions caused or mediated by galanin. Also provided are screening methods for identifying specific agonists and antagonists of the mammalian GalR3 receptors.
    Type: Grant
    Filed: June 26, 2007
    Date of Patent: August 26, 2008
    Assignee: Schering Corporation
    Inventors: Marvin Bayne, Tanaz Hashemi, Chaogang He, Suke Wang
  • Publication number: 20070255044
    Abstract: The present invention provides isolated mammalian GalR3 receptors, isolated or recombinant nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the receptors using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the receptors and are useful for treating medical conditions caused or mediated by galanin. Also provided are screening methods for identifying specific agonists and antagonists of the mammalian GalR3 receptors.
    Type: Application
    Filed: June 26, 2007
    Publication date: November 1, 2007
    Inventors: Marvin Bayne, Tanaz Hashemi, Chaogang He, Suke Wang
  • Patent number: 7250163
    Abstract: The present invention provides isolated mammalian GalR3 receptors, isolated or recombinant nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the receptors using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the receptors and are useful for treating medical conditions caused or mediated by galanin. Also provided are screening methods for identifying specific agonists and antagonists of the mammalian GalR3 receptors.
    Type: Grant
    Filed: September 22, 2004
    Date of Patent: July 31, 2007
    Assignee: Schering Corporation
    Inventors: Marvin Bayne, Tanaz Hashemi, Chaogang He, Suke Wang
  • Publication number: 20070117155
    Abstract: The present invention provides an isolated mammalian histamine receptor, isolated or recombinant nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods of making the receptor using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the receptor and are useful for treating medical conditions caused or mediated by histamine. Also provided are screening methods for identifying specific agonists and antagonists of the mammalian histamine receptor.
    Type: Application
    Filed: January 5, 2007
    Publication date: May 24, 2007
    Inventors: Jiang Behan, Joseph Hedrick, Thomas Laz, Frederick Monsma, Kelley Morse, Shelby Umland, Suke Wang
  • Patent number: 7166705
    Abstract: The present invention provides an isolated mammalian histamine receptor, isolated or recombinant nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods of making the receptor using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the receptor and are useful for treating medical conditions caused or mediated by histamine. Also provided are screening methods for identifying specific agonists and antagonists of the mammalian histamine receptor.
    Type: Grant
    Filed: July 8, 2003
    Date of Patent: January 23, 2007
    Assignee: Schering Corporation
    Inventors: Jiang X. Behan, Joseph A. Hedrick, Thomas M. Laz, Frederick J. Monsma, Kelley L. Morse, Shelby P. Umland, Suke Wang
  • Patent number: 6939953
    Abstract: The present invention provides an isolated mammalian leukotriene receptor, isolated or recombinant nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods of making the receptor using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the receptor and are useful for treating medical conditions caused or mediated by leukotriene. Also provided are screening methods for identifying specific agonists and antagonists of the mammalian leukotriene receptor.
    Type: Grant
    Filed: March 22, 2002
    Date of Patent: September 6, 2005
    Assignee: Schering Corporation
    Inventors: Suke Wang, Ling Pang, Thomas M. Laz
  • Publication number: 20050074768
    Abstract: The present invention provides an isolated mammalian histamine receptor, isolated or recombinant nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods of making the receptor using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the receptor and are useful for treating medical conditions caused or mediated by histamine. Also provided are screening methods for identifying specific agonists and antagonists of the mammalian histamine receptor.
    Type: Application
    Filed: July 8, 2003
    Publication date: April 7, 2005
    Inventors: Jiang Behan, Joseph Hedrick, Thomas Laz, Frederick Monsma, Kelley Morse, Shelby Umland, Suke Wang
  • Publication number: 20050026213
    Abstract: The present invention provides isolated mammalian GalR3 receptors, isolated or recombinant nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the receptors using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the receptors and are useful for treating medical conditions caused or mediated by galanin. Also provided are screening methods for identifying specific agonists and antagonists of the mammalian GalR3 receptors.
    Type: Application
    Filed: September 22, 2004
    Publication date: February 3, 2005
    Inventors: Marvin Bayne, Tanaz Hashemi, Chaogang He, Suke Wang
  • Publication number: 20040136984
    Abstract: The present invention provides isolated mammalian GalR3 receptors, isolated or recombinant nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the receptors using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the receptors and are useful for treating medical conditions caused or mediated by galanin. Also provided are screening methods for identifying specific agonists and antagonists of the mammalian GalR3 receptors.
    Type: Application
    Filed: February 13, 2004
    Publication date: July 15, 2004
    Inventors: Marvin Bayne, Tanaz Hashemi, Chaogang He, Suke Wang
  • Patent number: 6693182
    Abstract: The present invention provides isolated mammalian GalR3 receptors, isolated or recombinant nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the receptors using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the receptors and are useful for treating medical conditions caused or mediated by galanin. Also provided are screening methods for identifying specific agonists and antagonists of the mammalian GalR3 receptors.
    Type: Grant
    Filed: August 22, 1997
    Date of Patent: February 17, 2004
    Assignee: Schering Corporation
    Inventors: Marvin Bayne, Tanaz Hashemi, Chaogang He, Suke Wang
  • Patent number: 6613533
    Abstract: The present invention provides an isolated mammalian histamine receptor, isolated or recombinant nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods of making the receptor using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the receptor and are useful for treating medical conditions caused or mediated by histamine. Also provided are screening methods for identifying specific agonists and antagonists of the mammalian histamine receptor.
    Type: Grant
    Filed: March 19, 2001
    Date of Patent: September 2, 2003
    Assignee: Schering Corporation
    Inventors: Jiang X. Behan, Joseph A. Hedrick, Thomas M. Laz, Frederick J. Monsma, Kelley L. Morse, Shelby P. Umland, Suke Wang
  • Publication number: 20020156241
    Abstract: The present invention provides an isolated mammalian leukotriene receptor, isolated or recombinant nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods of making the receptor using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the receptor and are useful for treating medical conditions caused or mediated by leukotriene. Also provided are screening methods for identifying specific agonists and antagonists of the mammalian leukotriene receptor.
    Type: Application
    Filed: March 22, 2002
    Publication date: October 24, 2002
    Inventors: Suke Wang, Ling Pang, Thomas M. Laz
  • Patent number: 6465212
    Abstract: The present invention provides an isolated mammalian leukotriene receptor, isolated or recombinant nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods of making the receptor using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the receptor and are useful for treating medical conditions caused or mediated by leukotriene. Also provided are screening methods for identifying specific agonists and antagonists of the mammalian leukotriene receptor.
    Type: Grant
    Filed: September 20, 1999
    Date of Patent: October 15, 2002
    Assignee: Schering Corporation
    Inventors: Suke Wang, Ling Pang, Thomas M. Laz
  • Publication number: 20020098539
    Abstract: The present invention provides an isolated mammalian histamine receptor, isolated or recombinant nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods of making the receptor using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the receptor and are useful for treating medical conditions caused or mediated by histamine. Also provided are screening methods for identifying specific agonists and antagonists of the mammalian histamine receptor.
    Type: Application
    Filed: March 19, 2001
    Publication date: July 25, 2002
    Inventors: Jiang X. Behan, Joseph A. Hedrick, Thomas M. Laz, Frederick J. Monsma, Kelley L. Morse, Shelby P. Umland, Suke Wang
  • Patent number: 6204017
    Abstract: The present invention provides an isolated mammalian histamine receptor, isolated or recombinant nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods of making the receptor using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the receptor and are useful for treating medical conditions caused or mediated by histamine. Also provided are screening methods for identifying specific agonists and antagonists of the mammalian histamine receptor.
    Type: Grant
    Filed: October 7, 1999
    Date of Patent: March 20, 2001
    Assignee: Schering Corporation
    Inventors: Jiang X. Behan, Joseph A. Hedrick, Thomas M. Laz, Frederick J. Monsma, Kelley L. Morse, Shelby P. Umland, Suke Wang